Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

228.38
+5.692.55%
Volume:426.65K
Turnover:97.72M
Market Cap:15.12B
PE:17.40
High:233.96
Open:225.08
Low:223.96
Close:222.69
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.82
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):13.12
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.40
PE(LYR):-51.70

Loading ...

Ascendis Pharma Director Lars Holtug Disposes of 236 Shares Worth $62,337.59

Reuters
·
Sep 04

Ascendis Pharma is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 03

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $312 from $304

THOMSON REUTERS
·
Sep 02

Oppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Sep 02

Ascendis Pharma Price Target Maintained with a $327.00/Share by Wedbush

Dow Jones
·
Sep 01

H.C. Wainwright trims Ascendis target, says litigation overhang removed

TIPRANKS
·
Aug 31

Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345

THOMSON REUTERS
·
Aug 31

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Aug 31

Movement Alert|Ascendis Pharma A/S Rises 5.92% in Regular Trading, Global Patent Settlement Reached with BioMarin Over Yuviwel

Market Focus
·
Aug 31

Ascendis Pharma price target lowered to $330 from $333 at Jefferies

TIPRANKS
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Aug 31

Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target

MT Newswires Live
·
Aug 27

Ascendis Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Aug 27

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026

Reuters
·
Aug 26